Global brokerage firm CLSA has maintained its outperform rating on Apollo Hospital Enterprise with a target price of Rs 4,470 but it sees higher than expected cash burn for digital expansion as a key risk. "Mid-teen revenue growth with an improved margin for hospitals in FY23 likely," it said. "Apollo's 24x7 cash burn should continue in FY24, even if external funding is delayed," it added.
